Bausch Health Companies Inc. Payments for Repurchase of Other Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Bausch Health Companies Inc. payments for repurchase of other equity for the quarter ending 2011-12-31 was -$1.00K.
- Bausch Health Companies Inc. payments for repurchase of other equity for the quarter ending 2011-09-30 was $66.86M.
- Bausch Health Companies Inc. payments for repurchase of other equity for fiscal 2013 was $0.00.
- Bausch Health Companies Inc. payments for repurchase of other equity for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Bausch Health Companies Inc. payments for repurchase of other equity for fiscal 2011 was $66.86M, a 77.44% increase from fiscal 2010.
- Bausch Health Companies Inc. payments for repurchase of other equity for fiscal 2010 was $37.68M.
| Period end | Payments for Repurchase of Other Equity 3 month | Payments for Repurchase of Other Equity 12 month |
|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-28 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 | |
| 2011-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $66.86M 10-K · filed 2014-02-28 |
| 2011-09-30 | $66.86M 10-Q · filed 2012-11-05 | |
| 2010-12-31 | $37.68M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |